The role of soluble fiber intake in patients under highly effective lipid-lowering therapy

Silvia C Ramos, Francisco A Fonseca, Soraia H Kasmas, Flávio T Moreira, Tatiana Helfenstein, Ney C Borges, Ronilson A Moreno, Vinicius M Rezende, Fernanda C Silva, Maria C Izar, Silvia C Ramos, Francisco A Fonseca, Soraia H Kasmas, Flávio T Moreira, Tatiana Helfenstein, Ney C Borges, Ronilson A Moreno, Vinicius M Rezende, Fernanda C Silva, Maria C Izar

Abstract

Background: It has been demonstrated that statins can increase intestinal sterol absorption. Augments in phytosterolemia seems related to cardiovascular disease.

Objective: We examined the role of soluble fiber intake in endogenous cholesterol synthesis and in sterol absorption among subjects under highly effective lipid-lowering therapy.

Design: In an open label, randomized, parallel-design study with blinded endpoints, subjects with primary hypercholesterolemia (n = 116) were assigned to receive during 12 weeks, a daily dose of 25 g of fiber (corresponding to 6 g of soluble fibers) plus rosuvastatin 40 mg (n = 28), rosuvastatin 40 mg alone (n = 30), sinvastatin 40 mg plus ezetimibe 10 mg plus 25 g of fiber (n = 28), or sinvastatin 40 mg plus ezetimibe 10 mg (n = 30) alone.

Results: The four assigned therapies produced similar changes in total cholesterol, LDL-cholesterol, and triglycerides (p < 0.001 vs. baseline) and did not change HDL-cholesterol. Fiber intake decreased plasma campesterol (p < 0.001 vs. baseline), particularly among those patients receiving ezetimibe (p < 0.05 vs. other groups), and β-sitosterol (p = 0.03 vs. baseline), with a trend for lower levels in the group receiving fiber plus ezetimibe (p = 0.07). Treatment with rosuvastatin alone or combined with soluble fiber was associated with decreased levels of desmosterol (p = 0.003 vs. other groups). Compared to non-fiber supplemented individuals, those treated with fibers had weight loss (p = 0.04), reduced body mass index (p = 0.002) and blood glucose (p = 0.047).

Conclusion: Among subjects treated with highly effective lipid-lowering therapy, the intake of 25 g of fibers added favorable effects, mainly by reducing phytosterolemia. Additional benefits include improvement in blood glucose and anthropometric parameters.

Figures

Figure 1
Figure 1
Box plots of (A) Weight, (B) BMI, (C) Campesterol and (D) Glucose at baseline (white bars) and 12 weeks (dashed bars). Fiber-supplemented subjects presented mild reduction in body weight (*p = 0.04 vs. non-fiber supplemented, Student's paired t-test), body mass index (*p = 0.002 vs. non-fiber supplemented, Student's paired t-test), reduction in campesterol levels (*p = 0.033 vs. non-fiber supplemented, Student's paired t-test; †p = 0.025 vs. non-fiber supplemented, Student's independent t-test) and in blood glucose (†p = 0.035 vs. non-fiber supplemented, Student's independent t-test). BMI = body mass index.

References

    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
    1. Ortega RM, Palencia A, Lopez-Sobaler AM. Improvement of cholesterol levels and reduction of cardiovascular risk via the consumption of phytosterols. Br J Nutr. 2006;96(Suppl 1):S89–93.
    1. Theuwissen E, Mensink RP. Water-soluble dietary fibers and cardiovascular disease. Physiol Behav. 2008;94(2):285–92. doi: 10.1016/j.physbeh.2008.01.001.
    1. Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis. 2006;16(1):13–21. doi: 10.1016/j.numecd.2005.04.001.
    1. Patel MD, Thompson PD. Phytosterols and vascular disease. Atherosclerosis. 2006;186(1):12–9. doi: 10.1016/j.atherosclerosis.2005.10.026.
    1. Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, Stanek EJ, Li W, Pagoto SL, Hafner AR, Ockene IS. Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr. 2006;83(4):760–6.
    1. Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol. 2007;99(5):681–5. doi: 10.1016/j.amjcard.2006.09.117.
    1. van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009;50(4):730–9.
    1. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22(10):2041–53. doi: 10.1185/030079906X132721.
    1. Grodos D, Tonglet R. Scandinavian simvastatin study (4S) Lancet. 1994;344(8939-8940):1768. doi: 10.1016/S0140-6736(94)92907-6.
    1. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med. 2003;141(2):131–7. doi: 10.1067/mlc.2003.9.
    1. Plat J, Bragt MC, Mensink RP. Common sequence variations in ABCG8 are related to plant sterol metabolism in healthy volunteers. J Lipid Res. 2005;46(1):68–75.
    1. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 2007;14(3):99–108. doi: 10.5551/jat.14.99.
    1. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H. Finnish Treat-to-Target Study Investigators. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med. 2003;141(2):131–7. doi: 10.1067/mlc.2003.9.
    1. Miettinen TA, Gylling H. Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Atherosclerosis. 2003;168(2):343–9. doi: 10.1016/S0021-9150(03)00106-0.
    1. Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008;24(1):249–59. doi: 10.1185/030079908X253663.
    1. Matthan NR, Pencina M, LaRocque JM, Jacques PF, D'Agostino RB, Schaefer EJ, Lichtenstein AH. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res. 2009;50(9):927–35.
    1. Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, Sneyd MJ, Key TJ, Roe L, Day NE. Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and estimated-diet records. Br J Nutr. 1994;72(4):619–43.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
    1. Marlett JA, McBurney MI, Slavin JL. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc. 2002;102(7):993–1000. doi: 10.1016/S0002-8223(02)90228-2.
    1. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30–42.
    1. Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Health benefits of dietary fiber. Nutr Rev. 2009;67(4):188–205. doi: 10.1111/j.1753-4887.2009.00189.x.
    1. Anderson JW. Dietary fiber, lipids and atherosclerosis. Am J Cardiol. 1987;60(12):17G–22G. doi: 10.1016/0002-9149(87)90587-X.
    1. Gylling H, Puska P, Vartiainen E, Miettinen TA. Serum sterols during stanol ester feeding in a mildly hypercholesterolemic population. J Lipid Res. 1999;40(4):593–600.
    1. Ketomaki A, Gylling H, Miettinen TA. Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject. J Lab Clin Med. 2004;143(4):255–62. doi: 10.1016/j.lab.2003.11.007.
    1. Miettinen TA, Gylling H. The effects of statins and sitosterols: benefit or not? Curr Atheroscler Rep. 2009;11(1):23–7. doi: 10.1007/s11883-009-0004-z.
    1. Davis HR Jr, Altmann SW. Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta. 2009;1791(7):679–83.
    1. Salas-Salvado J, Farres X, Luque X, Narejos S, Borrell M, Basora J, Anguera A, Torres F, Bulló M, Balanza R. Fiber in Obesity-Study Group. Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial. Br J Nutr. 2008;99(6):1380–7.
    1. Tucker LA, Thomas KS. Increasing total fiber intake reduces risk of weight and fat gains in women. J Nutr. 2009;139(3):576–81. doi: 10.3945/jn.108.096685.
    1. Vuksan V, Rogovik AL, Jovanovski E, Jenkins AL. Fiber facts: benefits and recommendations for individuals with type 2 diabetes. Curr Diab Rep. 2009;9(5):405–11. doi: 10.1007/s11892-009-0062-1.
    1. Panahi S, Ezatagha A, Temelli F, Vasanthan T, Vuksan V. Beta-glucan from two sources of oat concentrates affect postprandial glycemia in relation to the level of viscosity. J Am Coll Nutr. 2007;26(6):639–44.
    1. Mello VD, Laaksonen DE. Dietary fibers: current trends and health benefits in the metabolic syndrome and type 2 diabetes. Arq Bras Endocrinol Metabol. 2009;53(5):509–18. doi: 10.1590/S0004-27302009000500004.
    1. Kim H, Stote KS, Behall KM, Spears K, Vinyard B, Conway JM. Glucose and insulin responses to whole grain breakfasts varying in soluble fiber, beta-glucan: a dose response study in obese women with increased risk for insulin resistance. Eur J Nutr. 2009;48(3):170–5. doi: 10.1007/s00394-009-0778-3.
    1. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–9. doi: 10.2337/dc09-0738.
    1. Sattar N, Preiss D, Murray HM, Paul Welsh, Brendan Buckley M, Anton de Craen JM, Sreenivasa Rao Kondapally Seshasai, John McMurray J, Dilys Freeman J, Wouter Jukema J, Peter Macfarlane W, Chris Packard J, David Stott J, Rudi Westendorp G, James Shepherd, Barry Davis R, Sara Pressel L, Roberto Marchioli, Rosa Maria Marfisi, Aldo Maggioni P, Luigi Tavazzi, Gianni Tognoni, John Kjekshus. et al.Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42. doi: 10.1016/S0140-6736(09)61965-6.
    1. Cholesterol Treatment Trialists' (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. doi: 10.1016/S0140-6736(10)61350-5.

Source: PubMed

3
S'abonner